HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Surfactant therapy for neonatal respiratory distress syndrome: a review of Korean experiences over 17 years.

Abstract
We undertook a multi-hospital collective study to evaluate outcomes of neonatal respiratory distress syndrome (RDS) patients treated with pulmonary surfactant (PS) over 17 yr in Korea (Group I; 1990/91, Group II; 1996, Group III; 2002, and Group IV; 2007). There were 60 neonates in Group I (16 hospitals), 1,179 in Group II (64), 1,595 in Group III (62), and 1,921 in Group IV (57). We adopted Bomsel's classification to evaluate initial chest radiographic findings, categorized RDS severities, and classified response types to PS therapy. Almost all cases were treated using a single dose in Groups I and II, but 19.5% received multiple-dose therapy in Group IV. In Group IV, Bomsel's stages III and IV composed 62.9% and initial severities of mild, moderate, and severe RDS were 23.0%, 42.0%, and 35.0%. More infants showed good response in Groups II, III, and IV than in Group I (71.7%, 66.8%, and 69.2% vs. 58.3%). Complications and mortality rate were lower in Group IV than in Groups I, II, and III (mortality rate: 14.3% vs. 40.0%, 30.0%, and 18.7%). We conclude that PS therapy in neonates with RDS had a remarkable impact on improving clinical course and outcomes over 17 yr in Korea.
AuthorsChong-Woo Bae, Won-Ho Hahn
JournalJournal of Korean medical science (J Korean Med Sci) Vol. 24 Issue 6 Pg. 1110-8 (Dec 2009) ISSN: 1598-6357 [Electronic] Korea (South)
PMID19949668 (Publication Type: Journal Article, Multicenter Study, Review)
Chemical References
  • Pulmonary Surfactants
Topics
  • Birth Weight
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature, Diseases (epidemiology, mortality, pathology, therapy)
  • Korea (epidemiology)
  • Longitudinal Studies
  • Pregnancy
  • Pulmonary Surfactants (therapeutic use)
  • Radiography, Thoracic
  • Respiratory Distress Syndrome, Newborn (epidemiology, mortality, pathology, therapy)
  • Surveys and Questionnaires
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: